{"product_id":"cedars-sinai-research-updates-in-lymphoma-2025","title":"Cedars Sinai Research Updates in Lymphoma 2025","description":"\u003ch3\u003eCedars Sinai Research Updates in Lymphoma 2025\u003c\/h3\u003e\r\n\u003cstrong\u003eInclude: 4 videos + 22 pdfs, size: 6.5 GB\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eTarget Audience: hematologists, oncologists, pathologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eInformation:\u003c\/strong\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\r\n\r\nDate \u0026amp; Location Saturday, October 18, 2025, 7:30 AM – Sunday, October 19, 2025, 3:00 PM PT, Cedars-Sinai Pavilion Education Center, Los Angeles, CA\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Hematology, Imaging, Internal Medicine, Oncology, Pathology \u0026amp; Laboratory Medicine, Radiation Oncology, Radiology, Surgery\u003c\/div\u003e\r\n\u003cdiv\u003e\n\u003cem\u003eProfessions\u003c\/em\u003e – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Physician Assistant, Researcher (non-physician), Researcher (physician)\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\r\nThis conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, “How I Treat” sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.\r\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eRecognize the utility of molecular testing in the classification and treatment of lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eDescribe new treatments under development including bi specific antibodies and CART therapies\u003c\/li\u003e\r\n \t\u003cli\u003eCollaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n \r\n\r\n\u003cstrong\u003e Topics:\u003c\/strong\u003e\r\n\u003cdiv class=\"6u 12u(small)\"\u003e\r\n\u003ch3 class=\"boxAgendaTitle\"\u003eSaturday, October 18, 2025\u003c\/h3\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 1: Hot Topics in Clinical Lymphoma – Part I\u003c\/div\u003e\r\nSession Chair: TBD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eFrontline Therapy for Advanced Hodgkin Lymphoma: ECHELON-1, SWOG S1826, and GHSG HD21 (BrECADD) Updates\u003c\/strong\u003e\r\n8:10AM – 8:35AM\r\nJoe Schroers-Martin, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNovel Approaches in First-Line DLBCL: Beyond R-CHOP POLARIX, Zilovertamab Vedotin + R-CHP Updates\u003c\/strong\u003e\r\n8:35AM – 9:00AM\r\nMatthew G. Mei, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDual Targeting CART for Lymphoma\u003c\/strong\u003e\r\n9:00AM – 9:25AM\r\nAkil Merchant, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBreak and Exhibits\u003c\/strong\u003e\r\n9:25AM – 10:10AM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 2: Hot Topics in Clinical Lymphoma – Part II\u003c\/div\u003e\r\nSession Chair: Justin Darrah\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eT-Cell Lymphoma\u003c\/strong\u003e\r\n10:10AM – 10:35AM\r\nWen-Kai Weng, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRole of Radiation Therapy in Lymphoma\u003c\/strong\u003e\r\n10:35AM – 11:00AM\r\nParag Sanghvi, MD\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eLightning Round\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eLightning Round: Open Clinical Trials for Lymphoma in LA area (90 sec per trial)\u003c\/strong\u003e\r\n11:00AM – 11:30AM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eLunch and Networking\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eLunch and Exhibits\u003c\/strong\u003e\r\n11:30AM – 12:15PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 3: Keynote \u0026amp; Basic Science Insights\u003c\/div\u003e\r\nSession Chair: Akil Merchant, MD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eKEYNOTE ADDRESS: Spatial Profiling in Lymphoma Transformers: More than Meets the Eye\u003c\/strong\u003e\r\n12:15PM – 1:00PM\r\nMina Xu, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMicroenvironment in Non-Hodgkin Lymphoma\u003c\/strong\u003e\r\n1:00PM – 1:20PM\r\nAnthony R Colombo, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eHidden Opponents: The DLBCL Microenvironment\u003c\/strong\u003e\r\n1:20PM – 1:40PM\r\nDavid Russler-Germain, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMetabolic Profiling and Modulation of the Lymphoma Microenvironment\u003c\/strong\u003e\r\n1:40PM – 2:00PM\r\nAkil Merchant, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBreak and Exhibits\u003c\/strong\u003e\r\n2:00PM – 2:20PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 4: Next Generation Diagnostics and Biomarkers\u003c\/div\u003e\r\nSession Chair: Joseph C. Lownik, MD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eLymphoma Biomarker Development: Lessons Learned from Gene Expression Profiling\u003c\/strong\u003e\r\n2:20PM – 2:50PM\r\nLisa M Rimsza, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDeveloping an Automated Multiplex IF for Diagnostic\/Biomarker Use in Lymphoma\u003c\/strong\u003e\r\n2:50PM – 3:10PM\r\nJoseph C. Lownik, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRole of ct DNA in Lymphoma\u003c\/strong\u003e\r\n3:10PM – 3:30PM\r\nBrian Sworder, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAssessments and Therapies for Older Patients with Aggressive Lymphomas\u003c\/strong\u003e\r\n3:30PM – 3:50PM\r\nElizabeth Brem, MD\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMolecular Determinants of Sensitivity to Polatuzumab-Vedotin in DLBCL\u003c\/strong\u003e\r\n3:50PM – 4:10PM\r\nSean R Corcoran , MD, PhD\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAdjourn\u003c\/strong\u003e\r\n4:10PM – 4:15PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eNetworking Reception\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNetworking Reception\u003c\/strong\u003e\r\n4:15PM – 5:30PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"6u 12u(small)\"\u003e\r\n\u003ch3 class=\"boxAgendaTitle\"\u003eSunday, October 19, 2025\u003c\/h3\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 1: CAR-T Cell Therapy: Managing Complex Toxicities\u003c\/div\u003e\r\nSession Chair: Hitomi Hosoya, MD, PhD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMechanisms of Neurotoxicity with IEC and Bispecific Therapies\u003c\/strong\u003e\r\n8:00AM – 8:20AM\r\nJuliane Gust, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eIEC-HS: Diagnosis (ASTCT Criteria), Pathophysiology, and Management\u003c\/strong\u003e\r\n8:20AM – 8:40AM\r\nHrishikesh Srinagesh, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eProphylactic Strategies for CAR-T Toxicities: Role of Early Steroids, Anakinra, and Other Novel Approaches\u003c\/strong\u003e\r\n8:40AM – 9:00AM\r\nCaspian Oliai, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eSecondary and T-cell Malignancies after CAR T-cell Therapy\u003c\/strong\u003e\r\n9:00AM – 9:20AM\r\nHitomi Hosoya, MD, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBreak and Exhibits\u003c\/strong\u003e\r\n9:20AM – 9:35AM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 2: Clinical Debate–What is the Optimal Bridging Strategy for CAR-T Therapy\u003c\/div\u003e\r\nSession Chair: Justin Darrah, MD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eIntro: Why bridging?\u003c\/strong\u003e\r\n9:35AM – 9:40AM\r\nJustin Darrah, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRole of Bispecifics as Bridging\u003c\/strong\u003e\r\n9:40AM – 9:50AM\r\nJustin Darrah, MD\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eRadiation as Bridging\u003c\/strong\u003e\r\n9:50AM – 10:00AM\r\nParag Sanghvi, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eOptimal Chemotherapy for Bridging\u003c\/strong\u003e\r\n10:00AM – 10:10AM\r\nDavid R. Oveisi, MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eDebate and Discussion\u003c\/strong\u003e\r\n10:10AM – 10:35AM\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBREAK\/EXHIBITS\u003c\/strong\u003e\r\n10:35AM – 11:05AM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv\u003e\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgendaTitle agendaBlue\"\u003e\r\n\u003cdiv\u003eSession 3: Next Generation Cellular Therapies for Lymphoma and Beyond (Non Accredited)\u003c\/div\u003e\r\nSession Chair: Yvonne Chen, PhD\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eNovel CART for Solid Tumors\u003c\/strong\u003e\r\n11:05AM – 11:25AM\r\nYvonne Chen, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eInnovations in TIL Therapy\u003c\/strong\u003e\r\n11:25AM – 11:50AM\r\nGiri Ramsingh , MD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eMacrophage Based Therapies\u003c\/strong\u003e\r\n11:50AM – 12:10PM\r\nAnn Liu, Other\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEngineered Protein Circuits for Cancer Therapy\u003c\/strong\u003e\r\n12:10PM – 12:30PM\r\nMichael B. Elowitz, PhD\u003c\/div\u003e\r\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"boxAgenda\"\u003e\r\n\u003cdiv class=\"row 50%\"\u003e\r\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eClosing and Lunch\u003c\/strong\u003e\r\n12:30PM – 12:35PM\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954572071010,"sku":"MED-AMB06342","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Cedars-Sinai-Research-Updates-in-Lymphoma-2025.jpg?v=1779379957","url":"https:\/\/meducourse.com\/products\/cedars-sinai-research-updates-in-lymphoma-2025","provider":"Meducourse","version":"1.0","type":"link"}